Il significato clinico dell'ossido nitrico nell'asma by Pisi, Roberta
UNIVERSITA’ DEGLI STUDI DI PARMA 
 
DOTTORATO DI RICERCA IN FISIOPATOLOGIA RESPIRATORIA SPERIMENTALE 







The Clinical Value of Exhaled Nitric Oxide in Asthma 







Chiar.mo Prof. Emilio Marangio 
 
Tutor: 
Chiar.mo Prof. Alfredo Chetta 
 
         Dottoranda:  



















      



















            
 3 
INDEX  
            pag 
 
SUMMARY             4 
SOMMARIO             6 
ASTHMA and AIRWAY INFLAMMATION        8 
EXHALED NITRIC OXIDE         10 
CLINICAL APPLICATION OF EXHALED NITRIC OXIDE IN ASTHMA  11 
OBJECTIVES          14 
REFERENCES          18 
 
FIRST STUDY:  
“MEASUREMENT OF FRACTIONAL EXHALED NITRIC OXIDE  
BY A NEW PORTABLE DEVICE. COMPARISON WITH THE  
STANDARD TECNIQUE”          
ABSTRACT           21 
INTRODUCTION          22 
METHODS           23 
RESULTS           26 
DISCUSSION          27 
REFERENCES          36 
 
SECOND STUDY:            
“OVERWEIGHT IS ASSOCIATED WITH AIRFLOW OBSTRUCTION  
AND POOR DISEASE CONTROL BUT NOT TO EXHALED NITRIC  
OXIDE CHANGE IN AN ASTHMATIC POPULATION”      
ABSTRACT           38 
INTRODUCTION          39 
METHODS           40 
RESULTS           43 
DISCUSSION          44 
REFERENCES          53 
 
ACKNOWLEDGEMENTS         57 
 4 
SUMMARY 
Bronchial asthma is an inflammatory disease and measurement of biomarkers in exhaled 
breath has recently become an attractive approach to non-invasively monitor airway inflammation. 
In bronchial asthma, increased fractional exhaled nitric oxide (FeNO) concentration in exhaled 
breath has been shown to reflect the extent of eosinophilic inflammation. Moreover, the increase of 
FeNO levels are suppressed by inhaled corticosteroids (ICS).  
Therefore, monitoring of FeNO is a useful marker of inflammation in asthma and it has 
proven to be very effective in the differential diagnosis of allergic asthma, predicting the response 
to ICS  therapy. 
 
Several FeNO analyzers are commercially available. Because of great  advances in 
technology a wide range of hand-held FeNO analyzers and smaller less costly devices are now 
becoming available, making FeNO  measurement a routine test in  the  primary care of asthmatic 
patients.  In the first study we tested a new portable device to investigate correlation and agreement 
with the standard stationary device. 
 
Nowadays, overweight and obesity  are common conditions worldwide. In particular,  the 
incidence of  overweight and obesity in Italian people is estimated almost of 32% and 10%,  
respectively. Obesity has been considered as a proinflammatory state and therefore several studies 
have been investigated the relationship between elevated body mass index (BMI) and asthma. In the 
second study we aimed to investigate in a large cohort of  Italian asthmatic patients whether or not 
overweight patients were different from normal weight subjects both in terms of clinical and 
functional features and in terms of airway inflammation, as assessed by FeNO measurement.  
 
Although the clinical application of FeNO is still needed to be  fully clarified, the use of this 
marker in clinical practice is providing a useful adjunct to conventional tools for the assessment and 
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management of the respiratory disease.  There is a general agreement that the development of new 
techniques detecting the distinct patterns of biomarkers in exhaled breath heralds the beginning of 
the era of “Breathomics”. In this regard, future developments may include FeNO “breathograms” to 

























L’asma bronchiale è una patologia infiammatoria delle vie aeree. Negli ultimi anni, la 
misurazione di biomarkers nell’aria esalata è  diventata una metodica non invasiva di uso comune 
per la valutazione dell’infiammazione delle vie aeree.  
Nell’asma bronchiale, è stato dimostrato che valori elevati della frazione dell’ossido nitrico 
esalato (FeNO) riflettono il grado di infiammazione eosinofilica delle vie aeree. Inoltre, il 
trattamento con corticosteroidi inalatori (ICS) riduce i valori di FeNO. 
Di conseguenza, la misurazione del FeNO è un utile biomarker dell’infiammazione 
nell’asma ed è risultato essere un parametro molto efficace nella diagnosi differenziale dell’asma 
allergica in quanto predice la risposta al trattamento con ICS. 
 
 
In commercio sono disponibili diversi analizzatori del FeNO. Grazie al progresso della 
tecnologia sta diventando disponibile una grande varietà di analizzatori portatili, più piccoli e meno 
costosi, il che rende la misurazione del FeNO un test di routine nella pratica clinica dell’asma. Nel 
primo studio abbiamo testato un nuovo apparecchio portatile per valutarne la correlazione e la 
concordanza con l’apparecchio stanziale standard. 
 
Al giorno d’oggi, sovrappeso e obesità sono condizioni molto diffuse in tutto il mondo. 
Nello specifico, nella popolazione italiana la percentuale di persone in sovrappeso e obese è stimata 
rispettivamente intorno al 32% e 11%. L’obesità è considerata come uno stato pro-infiammatorio, 
pertanto diversi studi hanno approfondito la relazione tra elevato indice di massa corporea (Body 
Mass Index, BMI) e asma. Nel secondo studio ci siamo posti l’obiettivo di verificare se, in 
un’ampia coorte di pazienti asmatici italiani, i pazienti in sovrappeso differivano dai soggetti 
normopeso in termini di aspetti clinico-funzionali e di infiammazione delle vie aeree stimata con la 
misurazione del FeNO. 
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Nonostante le applicazioni cliniche del FeNO non siano ancora completamente validate, 
l’utilizzo di questo marker nella pratica clinica fornisce un valore aggiuntivo agli strumenti 
convenzionali nella valutazione ed il monitoraggio delle malattie respiratorie. C’è un consenso 
generale riguardo al fatto che lo sviluppo di nuove tecniche in grado di determinare i differenti 
patterns dei biomarkers nell’esalato segna l’inizio dell’era della “Breathomics”. A questo riguardo, 
futuri sviluppi potrebbero includere i “breathograms” del FeNO come metodica di supporto nella 





















ASTHMA and AIRWAY INFLAMMATION 
Asthma is a leading medical problem worldwide, which involves almost 300 millions people 
of each age and all countries throughout the world. 
Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular 
elements play a role. The chronic inflammation  is associated with airway hyperresponsiveness that 
leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing, particularly at 
night or in the early morning. These episodes are usually associated with widespread, but variable, 
airflow obstruction within the lung that is often reversible either spontaneously or with treatment 
(1). 
Although asthma is increasingly recognised as a syndrome comprising a number of 
inflammatory phenotypes, the most common pathological feature is airway inflammation, 
sometimes associated with airway structural changes (remodelling) and hyperresponsiveness. 
The airway inflammation involves upper and lower respiratory tracts. It is yielded by an 
increase of inflammatory cells, predominantly T lymphocythes,  eosinophils, mast cells and also 
neutrophils, which  release specific mediators of the asthmatic response.  
In detail, the mucosal mast cell degranulation produces cysteinyl leukotrienes, 
prostaglandins D2, a lot of pro-inflammatory cytokines (tumor necrosis factor alpha – TNF-α -, 
interleukins IL-3, IL-4) and histamine,  acting on the hyperresponsive smooth muscle that induce 
airway obstruction and inflammation (2). Activated eosinophils release basic proteins, eotaxin, 
TNF-α, IL-3, IL-5, GM-CSF (granulocyte macrophage-colony stimulating factor) which amplify 
the inflammatory response and the airway remodelling (3). T CD4+ lymphocytes are present in an 
increased number, mainly Th2, releasing cytokines such as IL-4, IL-5, IL-9, IL-13 that regulate the 
eosinophilic inflammation and IgE production by B lymphocytes (4). The macrophages induce 
inflammation by macrophage-derived chemokines (MDC) and stimulate the remodelling releasing 
growth factors, i.e. PDGF (platelet derived growth factor), b-FGF (basic fibroblasts growth factor) 
and TGF-β (transformation growth factor-beta) (5). 
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The pathogenesis of asthma also involve airway structural cells, such as epithelial cells, 
smooth muscle cells, endothelial cells, fibroblasts and myofibroblasts, that in turn produce 
inflammatory mediators and connective tissue components increasing airway narrowing, oedema,  
mucus hypersecretion and structural changes.   
This pattern of inflammation is the responsible for the cascade of events linking the initial 
stimulus to the final abnormality in airway function. Furthermore, the local and systemic effects 
prompted by the mediators involved in this response yield a further activation and recruitment of 
other inflammatory cells into the airway. This vicious mechanism leads to parallel inflammatory 
pathways through the release of specific enzymes by activated cells. One of these is nitric oxide 
synthase Type 2 (NOS2, inducible or iNOS), that produces nitric oxide (NO), a marker of airway 
inflammation in asthma (6). 
 
The clinical manifestations of asthma – symptoms, sleep disturbances, limitation of daily 
activity, impairment of lung function, use of rescue medications – can be controlled with 
appropriated treatment. When asthma is controlled, there should be no more than occasional 
recurrence of symptoms and severe exacerbations should be rare. (1) 
Using techniques to monitoring airway inflammation has  become a key area for research  
and may be helpful in the management, early detection of asthma flares, and to monitor long-term 
therapy.  
Among the clinical features concurring to the diagnosis of asthma, symptoms and 
pulmonary function testing are easily performed. On the other hand, assessment of airway 
inflammation is more difficult and the gold-standard (bronchial bronchoscopy with lavage and 
biopsy) is too invasive and may be hazardous for the patient. Thus, a considerable number of 
potential non-invasive biomarkers identified in exhaled breath, sputum, blood and urinary samples 
are nowadays preferred. Induced or spontaneously produced sputum analysis allows quantification 
of inflammatory  eosinophilic or neutrophilic cells and analysis of  exhaled gas or breath condensate 
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allows the detection of several volatile organic compound (VOCs) and non-volatile markers of 
inflammation and oxidative stress. Furthermore, measurement of fractional exhaled nitric oxide 
(FeNO) has been suggested as a non-invasive marker of airway inflammation in asthma (7). 
 
 
EXHALED NITRIC OXIDE 
Nitric oxide (NO) is a gaseous molecule that is present in virtually all human organ systems 
and freely diffuses across membranes. NO is synthesized by various cells types through the enzyme 
NO synthase (NOS), which is encoded by three different genes in the human genome and 
differentially expressed in the airways. NOS oxidizes L-arginine to L-citrulline with the generation 
of NO in a process both oxygen and NADPH dependents. There are three different isoenzymes of 
NOS: constitutive NOS (cNOS) isoforms, like neuronal NOS (nNOS or NOS1) - in neurons -, 
endothelial NOS (eNOS or NOS3) - in endothelial cells -, and inducible form (iNOS or NOS2) - in 
macrophages, T lymphocytes, neutrophils, eosinophils and epithelial cells -. Recently has been 
identified a fourth isoform, NOS4, a constitutive form potentially involved in end-stage renal 
disease and diabetic nephropathy (6). These isoforms differ in their capacity to produce NO and in 
the final effect of the NO produced. Both NOS1 and NOS3 are calcium and calmodulin-dependent. 
Agonists such as acetylcholine, bradykinin and histamine result  in an increase of calcium ions 
inducing cNOS to release picomolar concentrations of NO, which acts as a local regulatory factor, 
such as neurotransmission, vasodilator tone and cardiac contractility. The constitutive forms are 
corticosteroid-resistant, therefore basal levels of NO are not affected by these drugs (8). In contrast, 
NOS2 is calcium/calmodulin-independent. During inflammatory or infective disorders it is 
transcriptionally upregulated by inflammatory cytokines, such as TNFα, IFγ, IL1β, endotoxin, 
lipopolysaccharides, viruses, bacteria and allergens, regardless of Ca2+ influx.  Once induced, 
within several hours NOS2 produces largest concentrations (nanomolar) of NO in the airway 
epithelium having a pro-inflammatory effect. It remains stable in the gaseous phase constituting the 
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main source of level of NO in the exhaled breath. NOS2 is glucocorticoid-sensitive. Therefore, its 
expression is up-regulated in subjects with allergic asthma whereas  is decreased in steroid-treated 
asthmatic patients (6). NO rapidly reacts with oxygen, superoxide anions, nucleotides, water, thiols, 
metalloproteins, amines and lipids to form  nitrites, nitrates, peroxynitrite, S-nitrosothiols, S-
nitrosamines, amplifying its physiological functions. In the lung, in addition to play a role in the 
inflammatory response, the chemical products of NO are involved in bronchodilatation, 
neurotransmission in bronchial smooth muscle, plasma exudation, oedema and vascular smooth 
muscle relaxation, through the release of cyclic guanosine monophosfate (cGMP). Moreover, NO 
participates in host defences due to its bactericidal and cytotoxic properties (9,10) (Fig.1). 
 
 
CLINICAL APPLICATION OF EXHALED NITRIC OXIDE IN ASTHMA 
Nitric oxide is a gas originally regarded damaging to human health as a toxic molecule of air 
pollution. After the first detection in coronary arteries of NO-free radical as endothelium-derived 
relaxing factor (EDRF) in 1987 (11,12), the advent of chemiluminescence analyzers in the early 
1990s allowed the detection of NO in exhaled breath (13). Afterwards, a large body of scientific 
works has confirmed that NO is a signalling molecule implicated both in biological processes and in 
pathological conditions, so that became the “Molecule of the Year” in 1992 (14). Patients with 
asthma were found to have higher levels of the fractional orally exhaled NO as compared with 
healthy subjects (7,15,16) that decreased in response to treatment with corticosteroids (17,18). This 
quickly prompted the evaluation of exhaled NO as a potential non-invasive method to diagnose 
asthma and monitor the response to anti-inflammatory therapy. Indeed, almost two key points 
converge to provide the rationale for the use and interpretation of FeNO measurements. Firstly, in 
asthma increased FeNO (>45ppb) reflects eosinophilic-mediated inflammatory pathways 
underlying both at the central and/or peripheral site of the airway. Conversely, a low FeNO            
(< 25ppb) may be regarded as a valued predictive marker for the absence of eosinophilic bronchial 
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inflammation (19). Thus, FeNO is a good surrogate marker to distinguish eosinophilic (i.e. allergic 
asthma) from non-eosinophlic pathologies, providing a complementary tool in aid to the 
conventional pulmonary testing in the assessment of patients with undiagnosed respiratory 
symptoms. Secondly, due to the close relationship between airway eosinophilia and steroid 
responsiveness,  FeNO may be used in clinical practice to predict the response to asthma controller 
therapy and identify the efficacy of inhaled corticosteroids (ICS) as well as to monitor compliance 
with ICS therapy or withdrawal in asthmatic patients (20). As such, it has been proved its potential 
use as a marker to predict asthma exacerbations (21,22).  
It should be emphasized that FeNO is related with other outcomes in allergic asthma, closely 
correlating with the percentage of eosinophils in samples of induced sputum, blood, BAL and 
bronchial reactivity (23,24), but without a significant correlation with lung function parameters. In a 
consensus statement on the clinical applications of this technique for the diagnosis and management 
of asthma, FeNO was recommended to be included among the standard parameters used into 
clinical care (25). A recent comprehensive review (19) analyzes several design issues of five 
randomized controlled algorithm asthma trials that reported only equivocal benefits of adding FeNO 
measurements to traditional diagnostic methods, such as spirometry. In conclusion, Barnes et al. 
(19) defined FeNO as “an important adjunct for diagnosis and management in selected cases of 
asthma…providing a non-invasive window into predominantly large-airway presumed eosinophilic 
inflammation”. Lastly, in a review evaluating the technical issues and confounding factors related 
to FeNO measurements, Kostikas et al. (26) concluded that FeNO represents the only exhaled 
biomarker that has reached clinical practice even in primary care setting.  
 
In comparison  with other techniques, the measurement of exhaled NO provides immediate 
results, is easier to implement, reproducible and feasible also in young subjects and patients with 
severe airflow obstruction, for whom other tests are difficult or impossible to perform. Due to its 
non-invasive nature, it can be easily performed in outpatient visits during the follow-up of asthmatic 
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patients. It also represents a cheaper technique as compared to standard clinical tools. A major 
disadvantage of use of NO exhaled as diagnostic test for asthma is represented by the confounding 
factors that might influence the value of  FeNO measurement, like infection of high airways, lung 
cancer or current medications. 
 
 
Measurements of nitric oxide 
In 1997, a taskforce of the European Respiratory Society (ERS) (27) and in 1999 the 
American Thoracic Society (ATS) (28) published statements, which defined the guidelines for 
adequate FeNO measurement, which have been updated in a joint document in 2005 (29,30). In 
clinical practice, there are two ways to measure the level of exhaled NO by either on-line or off-line 
methods, even though this last is considered obsolete and no longer recommendable. The on-line 
method uses techniques capable to evaluate the level of FeNO in exhaled air from a single breath 
exhalation, calculating FeNO value at the end-expiratory plateau. Exhalation should be performed 
at stable expiratory flow rate of 50ml/s. An immediate result is obtained and expressed in parts per 














The most widely used approach to FeNO measurement is chemiluminescence. In 2003 a 
FeNO stationary chemiluminescence analyzer (Niox; Aerocrine AB, Solna, Sweden) was approved 
by U.S. Food and Drug Administration for the use in asthma management (31). Nevertheless, 
generally chemiluminescence devices tend to be rather expensive, large and poorly portable. 
Therefore, smaller cheaper portable equipments based on an electrochemical cell technique are now 
available, allowing the assay possible in daily practice by general physicians and, in the near future, 
at home by patients.  
A new portable device (NObreath, Bedfont, Rochester, UK) has recently been developed but 
no published study has evaluated its reliability.  
The aim of our study was to compare FeNO values obtained by the new portable device to 
those of the standard stationary FeNO analyzer (Niox) in a large cohort of asthmatics, to investigate 
correlation and agreement with the standard device.  
 
Second Study 
Available literature on airway disease highlights a linked association between obesity and 
asthma, and several studies aimed to investigate the relationship between elevated BMI and asthma 
control, degree of severity and airway inflammation.  
In obese asthmatic patients, the characteristics of airway inflammation are complex. The 
adipose tissue may have a pro-inflammatory effects, by secreting cytokines, chemokines and 
adipokines, which likely generate a different pathways from the classic Th2 cytokine driven (32). 
However, discordant findings were reported on the relation between BMI and FeNO, since obesity 
was associated with lower, or higher or normal FeNO values (33). 
Furthermore, in the obese patients some comorbidities, including gastroesophageal reflux 
disease (GERD) and sleep disorders breathing, which may mimic asthma symptoms, may occur, by 
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inducing diagnostic issues. Notably, up to now, no study has been specifically addressed to 
investigate the relation between asthma and overweight, a condition in which the effects on lung 
mechanics as well as comorbidity are likely to be less remarkable than in morbidly obese patients. 
The aim of our study was to ascertain whether or not in a large cohort of asthmatic patients 
overweight patients were different from normal weight patients both in terms of clinical and 




















Figure 1. Schematic diagram of synthesis and functions of nitric oxide.  
Key: NOS = nitric oxide synthase; NADPH = the reduced form of NADP; NADP = Nicotinamide 
Adenine Dinucleotide Phosphate; NO = nitric oxide; cGMP = cyclic guanil monophosphate; NANC 
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“MEASUREMENT OF FRACTIONAL EXHALED NITRIC OXIDE BY A NEW 




Background: Fractional exhaled nitric oxide (FeNO) measurement is a reliable non-invasive 
marker of airway inflammation. The use of portable FeNO analyzers could enable the introduction 
of airway inflammation assessment in primary care.  
Objective: We compared FeNO values obtained by a new portable device (NObreath, Bedfont, UK) 
to those of the standard stationary analyzer (NIOX, Aerocrine, Sweden) in a large cohort of 
asthmatics. 
Methods: 154 (age range: 14-83 years, FEV1 range: 48 to 134% pred, asthma control test [ACT] 
range: 7-25) out of 168 recruited patients, completed the study. Each patient performed at least two 
valid FeNO measurements at a constant flow rate of 50ml/s on each of the two analyzers.  
Results: A significant relationship between the FeNO values obtained by the two devices (r = 0.95, 
p < 0.001) was found. Altman-Bland plot confirmed this agreement. Within-patient repeatability 
was excellent in both devices. Intraclass Correlation Coefficients for NIOX and NObreath values 
were 0.925 and 0.967, respectively. By means of receiver operating characteristic curve analysis the 
FeNO cutoff points which better identified patients with ACT ≥ 20 were 15 ppb (0.84 sensitivity 
and 0.42 specificity) by NIOX and 25 ppb (0.53 sensitivity and 0.69 specificity) by NObreath. 
Easiness to use of both devices, assessed by visual analogue scale was not different. 
Conclusion: FeNO measurements obtained by the new portable FeNO analyzer are reliable because 
they are directly comparable with those obtained by the stationary standard device. The use of 
portable instruments may facilitate the FeNO measurement in primary care.  
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INTRODUCTION 
The measurement of fractional exhaled nitric oxide (FeNO) is a reliable non-invasive marker 
of airway inflammation (1). FeNO has been shown to be increased in some airway diseases, such as 
asthma (2), allergic rhinitis (3), chronic rhinosinusitis (4) and chronic cough (5). Notably, FeNO 
measurement has been proved to play a role in asthma diagnosis (6) and management (7) and has 
become a clinical routine in asthmatic patients. 
 
The chemiluminescence analyzer is currently considered as the standard technique for 
measuring FeNO and a FeNO stationary chemiluminescence analyzer (NIOX, Aerocrine AB, Solna, 
Sweden) has been approved by the U.S.A. Food and Drug Administration for use in asthma 
management (8). However, limitations of the stationary device, such as cost, size and frequent 
calibration requirement, may preclude its wide-scale introduction into clinical practice. 
Furthermore, a portable FeNO analyzer could be extremely useful in primary care as an additional 
tool to improve care of asthmatic patients.  
 
A new portable device using electrochemical sensors (NObreath, Bedfont, Rochester, UK) 
has recently been developed but no published study has evaluated its reliability. The aim of the 
study was, therefore, to compare in a large group of asthmatic patients FeNO values obtained by the 
new portable device to those of the standard stationary chemiluminescence FeNO analyzer and to 
calculate a conversion equation. Additionally, we evaluated the within subject reproducibility of the 
FeNO values obtained by both devices as well as their capability to discriminate asthmatic patients 
with controlled disease from those with uncontrolled one. Lastly, we assessed the easiness to use of 







Asthmatic patients (14 years of age and older) with specialist-diagnosed asthma were 
eligible to take part in the study and were prospectively recruited over a 6-month period from our 
Asthma Outpatient Clinic. In each patient, duration of disease, atopy and smoking habit were 
recorded. No patient has undergone any FeNO measurement before the study.  
We ensured that the patient had followed the pre-test instructions, i.e. had consumed nitrate-
rich foods and beverages, including alcoholic ones, at least 1 h before the test, had not smoked 
tobacco products and had not practised exercise or tiring exertion for 1 h prior to testing and, 
finally, had not an acute respiratory infection in progress, as these factors can affect the test results. 
Moreover, all patients underwent FeNO measurement before lung function test. Only patients able 
to perform at least two acceptable FeNO measurements both on NIOX and on NObreath (up to six 
attempts per device) were included in the analysis.  




FeNO was measured according to the ATS/ERS guidelines (9) using a hand-held device 
NObreath (FeNONObreath) and a stationary NIOX (FeNONIOX). The order of the measurements was 
random. All tests were performed at the same time of day to allow a possible circadian rhythm 
effect. For both types of measurements, patients were seated in the upright position without a nose 
clip. In a subgroup of patients, the within subject reproducibility of FeNONObreath and FeNONIOX was 
assessed by repeating measurements on two separate days by 1 week. To participate to repeatability 
study, patients had to be in clinically stable conditions and had not to modify their therapeutic 
regimen and to show a change in FEV1 greater than 10% on the two study occasions. The repeated 
measurements were performed during the same time of the day (± 2 h). 
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In detail, FeNONObreath was obtained inviting the subjects to inhale as deeply as possible and 
after 3s, guided by an auditory cue, to exhale through the mouthpiece, keeping the ball in the flow 
indicator in the middle of the black band in the centre of the tube, at a constant flow rate of 50 ml/s. 
The required exhalation time is approximately 16s. To ensure a breath sample was taken at the 
correct flow rate, the monitor has been held upright at all times during the test. FeNONIOX was 
performed asking the subjects to inhale nitric oxide-free air through a filter connected to the device 
deeply to total lung capacity and then to exhale for 10s at a constant pressure guided by a visual cue 
to stabilize flow rate. All tests were performed at an exhalation pressure of 10-20 cm H2O, to 
maintain a fixed flow-rate of 50 ml/s. Measurements were repeated after a brief rest period until two 
acceptable values (±2.5 p.p.b. for measurements <50 p.p.b. and ±5% for measurements ≥50 p.p.b.) 
were performed (maximum six attempts). The mean of two adequate values for each subject was 
recorded for analysis. For NIOX the system calibration was performed every 14 days, whereas 
NObreath was set to zero every month. 
 
After FeNONObreath and FeNONIOX patients rated the easiness to use of both devices on an 
interval scale, which was a 100-mm horizontal visual analogue scale (VAS). The VAS consisted of 
a horizontal ruler without any mark on the patient’s side with the words “easy to use” and “not easy 
to use” on the left and right end, respectively. Easiness to use ratings were expressed in mm from 0 
to 100 and corresponded to the distance of the marker from the left end of the visual analogue scale.  
 
Lung function testing 
Lung function was measured by a flow-sensing spirometer connected to a computer for data 
analysis (CPFS/D Spirometer, MedGraphics, St Paul, MN, USA) which met American Thoracic 
Society (ATS) standards. Forced vital capacity (FVC), forced expiratory volume in the first second 
(FEV1), and FEV1/FVC ratio were recorded. FVC and FEV1 are expressed as percent of predicted 
value (10), FEV1/FVC as percent. 
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Asthma Control Assessment 
Asthma control was assessed using the Italian version of the Asthma Control Test (11). 
Patients subjectively evaluated the degree of impairment caused by their disease during the 
preceding 4 weeks by responding to five questions using a five-point-scale. The ACT is reliable, 
valid, and responsive to changes in asthma control over time (11). The sum of the scores of the five 
questions gave the total ACT score (range 5–25).  A cutoff score of 20 or more identifies patients 
with well controlled asthma.  
 
Statistical Analysis  
The distribution of variables was assessed by means of Kolmogorov-Smirnov Goodness-of-
Fit test. To normalize the distribution, FeNO data were log-transformed for analysis and reported as 
geometric mean ± GSEM. Other numerical variables were expressed as mean ± SD, unless 
otherwise specified. Paired t-test and unpaired t-test were used for comparisons, when appropriate. 
The relationship between measures was estimated by Pearson’s correlation coefficient (r) and linear 
regression analysis. The agreement between measures was assessed by the method of differences 
against the means according to Bland and Altman (12) and the Spearman correlation coefficient (rs) 
was used to identify any potential tendency for the separation of agreement at higher or lower 
values. The repeatability of measures was expressed as intraclass correlation coefficient (rI) (13). 
The receiver operating characteristic (ROC) curve method (14) was used to plot the true positive 
rate (sensitivity) in function of the false positive rate (100-specificity) for discriminating patients 
with asthma under control from those with poorly controlled asthma for each device. A p value  







One hundred sixty-eight asthmatic patients were enrolled. Fourteen patients were excluded 
after failing to perform acceptable FeNO measurements (six for NIOX, five for NObreath, one for 
both NIOX and NObreath, two unapproved values). A total of one hundred fifty-four consecutive 
patients (age range: 14-83 years, 54 males, 18 current smokers, 112 atopics) completed the study 
(Table 1). One hundred and seven patients (69%) were receiving therapy. In all patients, spirometry 
ranged from a severe ventilatory defect to normal value (FEV1 range: 48% to 134%) (Table 1). 
 
FeNONIOX and FeNONObreath values were significantly different (24.6 ppb ± 1.073 vs 22.6 
ppb ± 1.075, p= 0.0002) (Table 2) and were significantly related (r = 0.95, p < 0.001) with the 
following regression equation Log FeNONIOX = 0.287 (SE=0.078) + 0.935 (SE = 0.024) ∙ Log 
FeNONIOX (r
2
 = 0.91, p < 0.001) (Figure 1). The Bland and Altman plot showed a high degree of 
agreement between the devices (Figure 1) and Spearman correlation coefficient confirmed the lack 
of bias at either end of the range of values (rs = -0.088, p = 0.275). 
 
In the subgroup of 20 patients (age range: 19-70 years; 6 males), who performed the 
FeNONObreath and FeNONIOX reproducibility, spirometry did not significantly change in the two 
occasions (FVC = 111% pred  21 vs 106% pred  16; FEV1 = 100 % pred  19 vs 96 % pred  17;  
FEV1/FVC = 76 % pred  10 vs 76 % pred  10). In this subgroup of patients, FeNONIOX and 
FeNONObreath values obtained in the two occasions were respectively 21.8 ppb  1.18 and 21.0 ppb  
1.20 (rI = 0.925) and 19.1 ppb  1.20 and 19.9 ppb  1.19 (rI = 0.967) (Figure 2).    
 
Ninety-six patients out of 154 had well controlled asthma (ACT ≥ 20) and lower FeNONIOX 
and FeNONObreath values, as compared to patients with poorly controlled asthma (20.9 ppb  1.08 vs 
31.8 ppb  1.13, p = 0.004 and 19.9 ppb  1.08 vs 27.6 ppb  1.13, p = 0.041).  According to the 
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ROC curve method, the plot of the true-positive rate in function of the false-positive rate for 
different cutoff points of FeNONIOX and FeNONObreath values with respect to a ACT ≥ 20, as 
threshold value, showed respectively 0.644 (95% confidence interval [CI], 0.562 to 0.719; p = 
0.002) and 0.607 (95% CI, 0.525 to 0.684; p = 0.0251) area under curve (AUC) values. Pairwise 
comparisons of the ROC curves revealed a difference in the AUC of 0.0369 (95% CI, 0.004 to 
0.0697; p = 0.028) between the FeNONIOX and FeNONObreath values. The FeNONIOX and FeNONObreath 
cutoff points, which maximized sensitivity and specificity were 15 ppb (0.84 sensitivity and 0.42 
specificity) and 25 ppb (0.53 sensitivity and 0.69 specificity), respectively (Figure 3). Well 
controlled and poorly controlled patients did not differ in FEV1 values (95%  15 vs 93% 20, p = 
0.477).  
 
FeNONIOX required a significant greater number of attempts to obtain two acceptable values, 
as compared to FeNONObreath (p = 0.01). However, easiness to use of both devices, assessed by 




The results of the present study show that FeNO measurements obtained by NObreath, a 
new portable FeNO analyzer, are reliable because they are directly comparable with those obtained 
by NIOX, the stationary device currently considered as the standard for measuring FeNO. 
Furthermore, because of its manageability and easiness to use the portable device could be suitable 
for home-monitoring of asthma as well as for epidemiological studies. 
 
It is important to appreciate that FeNO measurements in both healthy subjects and asthmatic 
patients are right-skewed (15,16) and require appropriate transformation prior to statistical analysis. 
This may imply some difficulties for interpreting measurements obtained in clinical setting. In this 
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regard, we found a significant difference between FeNO values obtained by the two devices and the 
regression line in figure 1 does not dissect the origin of the axis, confirming a consistently higher 
value from the NIOX device compared with the NObreath device. We also provided the regression 
equation to convert FeNO values measured by NObreath into those obtained by NIOX. However, it 
is of note that the difference between the values measured by the two devices amounts to 
approximately 2 ppb, which would not be clinically significant.  
 
In the present study, Bland-Altman plot demonstrated agreement between both devices and, 
importantly, the difference between values obtained by the NObreath and NIOX did not change 
with increasing FeNO values. This finding is of clinical relevance since measurements with 
NObreath can be reliably performed in any asthmatic patient regardless of  the degree of airway 
inflammation. Moreover, the reliability of NObreath device is further supported by its excellent 
degree of within-subject repeatability over time (Intraclass Correlation Coefficient > 0.9). 
Furthermore, the repeatability of NObreath was similar to that of the stationary standard analyzer. 
Our data are in line with previous reports comparing agreement (15,16) and repeatability (16) 
between the stationary standard analyzer and the MINO, a portable device of FeNO measurement.  
 
In this study, we also assessed the capability to discriminate poorly controlled asthmatic 
patients from well controlled ones, by using the two FeNO measurement devices. As expected, we 
found that well controlled patients had significantly lower FeNO values, as compared to poorly 
controlled patients. Interestingly, this difference was found with both devices, even if the magnitude 
of the difference was greater with the standard device. Additionally, in our cohort of patients a 
FeNO value greater than 15 ppb obtained by NIOX or greater than 25 ppb obtained by NObreath 
had a high likelihood to be associated to poorly controlled asthma. According to the ROC curve 
analysis, NIOX sensitivity was higher than that of NObreath, which conversely showed higher 
specificity. The ROC AUC value generated using the NIOX device was higher than that of 
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NObreath. Taken together, our findings suggest that the portable device has a slightly lower 
discriminating power than the standard device, at least in terms of controlled versus uncontrolled 
asthma. Interestingly, our results are similar to those of a previous paper (15), which reported a 
slightly lower discriminating power of MINO, as compared to NIOX, to separate asthmatic patients 
from healthy subjects.     
 
We found that the number of attempts to achieve the required acceptable measurements was 
slightly, but significantly lower for NObreath than that for NIOX. This result is consistent with a 
previous report (17), which compared NIOX and MINO and reported a significantly less number of 
attempts needed to achieve the acceptable measurements by using MINO. This finding could at 
least partly be explained by the fact that some measurements in the NIOX may discarded after a 
linear regression analysis of the NO plateau has been performed, even though the number of 
regression failures was not recorded in the present study. The linearized plateau must not deviate 
more than 10% from the horizontal axis according to current guidelines (9). Notably, the difference 
in the number of attempts between the devices was not perceived by the patients in terms of 
different easiness to use of NIOX in comparison with NObreath. Easiness to use ratings assessed by 
the visual analogue scale were not different between NIOX and NObreath. 
 
In conclusion, this study shows that there is clinically acceptable agreement between the 
new portable NObreath and the stationary standard device NIOX. The repeatability of 
measurements obtained by NObreath was similar to those obtained by NIOX. In addition, FeNO 
measurements with both devices was a reliable method of differentiating well controlled from 
poorly controlled asthmatic patients. Lastly, more than 90% of the subjects of our large cohort of 
asthmatics with a wide spectrum of age were able to successfully use both devices. The use of 
portable instruments will enable the introduction of FeNO measurement in the primary health care.  
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Table 1. Characteristics of 154 patients with asthma 
 
Age (years) 43  16 
Sex (M/F) 0.54 
BMI (kg/m
2
) 25  5 
Atopy (Yes/No) 2.67 
Disease duration (years) 11  11 
Smoking habit (Yes/No) 0.13 
ACT (0-25) 21 (17-23) 
FVC (% of pred) 105  17 
FEV1 (% of pred) 94  17 
FEV1/FVC (% of pred) 75  10 
 
Values are expressed as mean  SD, ratio or median (25%-75% percentile) 
ACT = Asthma Control Test; BMI = Body Mass Index; FEV1= Forced Expiratory Volume at 1
st
 
second; FEV1/FVC = Forced Expiratory Volume at 1
st
 second/Forced Vital Capacity ratio; FVC = 










Table 2. FeNO values obtained by NIOX and NObreath devices, number of attempts to obtain 
at least two acceptable FeNO values by the devices and easiness to use of the devices.      
 
 NIOX NObreath p 
FeNO (ppb) 24.6 ± 1.073 22.6 ± 1.075 0.002 
Attempts (No.) 3 (2-4) 2 (2-3) 0.01 
Easiness (VAS, mm) 10 (0-22) 10 (0-22) 0.93 
 
Values are expressed as geometric mean  GSEM or median (25%-75% percentile) 


















Figures Legends  
 
Figure 1. Linear regression with 95% confidence interval (upper panel) and Altman-Bland plot 
(lower panel) of NObreath vs NIOX values in 154 asthmatic patients  
 
Figure 2. Within-subject repeatability of NIOX values (upper panel) and NObreath (lower panel) 
in 20 asthmatic patients. The intraclass correlation coefficients were 0.925 and 0.967, respectively. 
The continuous line is the line of identity.    
 
Figure 3. Receiver operating characteristic (ROC) curve analysis for different cutoff points of 
FeNO measurements obtained by NIOX (blue line) and by NObreath (green line) with respect to an 
Asthma Control Test score ≥ 20, as threshold value. Area under curve (AUC) values of NIOX and 
NObreath measurements were 0.644 (p = 0.002) and 0.607 (p = 0.0251), respectively. Pairwise 
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“OVERWEIGHT IS ASSOCIATED WITH AIRFLOW OBSTRUCTION AND POOR 





Background: The association between elevated body mass index (BMI) and asthma remains 
controversial.  
Objective: To investigate the relationship between overweight (BMI > 25 ≤ 30 kg/m²), lung 
function, disease control and airway inflammation in an asthmatic population.   
Methods: We consecutively studied 348 patients (43±16 yr; 211 F). In all patients, BMI, 
spirometry, Asthma Control Test (ACT) and Fractional Exhaled Nitric Oxide (FeNO, ppb) were 
measured. 
Results: 145 patients were overweight  and, as compared to those with normal BMI, had lower 
values of FVC, FEV1 and FEV1/FVC and of FEF25-75, even when normalized for FVC (p < 0.05 for 
each comparison). The ratio between the number of patients with well controlled asthma (ACT ≥ 
20) and that of patients with poor controlled asthma (ACT <20) was significantly lower in 
overweight patients (1.07 vs 1.84; χ2= 6.030, p<0.01). In overweight patients, the odds ratio of 
uncontrolled asthma expressed by logistic regression analysis was 1.632 (95% CI = 1.043-2.553), 
independently from gender, atopy, smoke and inhaled steroid therapy. No difference was observed 
in FeNO values between overweight and normal weight patients (39 ± 34 vs 40 ± 34 ppb). 
Conclusions: Our results shows that in an asthmatic population, the overweight is associated with 
airflow obstruction and poor disease control, but not to any FeNO change. The finding of the 
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present study support the view that other factors than airway inflammation alone may explain the 




In Western countries, asthma and obesity are chronic and prevalent conditions (1). 
Epidemiologic investigations have shown an association between obesity or elevated body mass 
index (BMI) and prevalent and incident asthma (1). However, the role of obesity in asthma control 
and severity remains unclear. As compared with normal weight patients, severe asthma was found 
to be more prevalent in obese patients (2), and obesity has been recognised as a risk factor for poor 
disease control (3). On the other hand, elevated BMI was associated with worse asthma control and 
quality of life, but not to asthma severity (4). Furthermore, among adults presenting to the 
emergency department with acute asthma, asthma exacerbations among obese and nonobese adults 
were similar (5). Lastly, using four validated asthma control questionnaires, Clerisme-Beaty et al 
(6) failed to find an association between obesity and asthma control in an urban population with 
asthma. 
 
It is also of note that the value of the airway inflammation in asthmatic patients with 
elevated BMI remains to be fully clarified (7). The measurement of fractional exhaled nitric oxide 
(FeNO), a reliable non-invasive marker of airway inflammation (8-11) which has become a clinical 
routine (12,13) in asthmatic patients, has provided conflicting results in patients with asthma, when 
categorized by BMI. As compared with normal weight patients, obese asthmatic patients showed 
lower (14,15), as well as higher (16,17) or similar (18,19) FeNO values.  
 
Discrepancies in reports on asthma-obesity relationship may be partly due to the fact that 
obesity may be associated with lung volume changes and comorbidity, such as gastroesophageal 
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reflux disease, which in obese patients may mimic asthma and may determine inaccuracy both in 
diagnosis and in severity grading of asthma. Notably, up to now, no study has been specifically 
addressed to investigate the relation between asthma and overweight, a condition in which the 
effects on lung mechanics as well as comorbidity are likely to be less remarkable than in morbidly 
obese patients. 
 
The aim of the present study was to ascertain whether or not in a large cohort of asthmatic 
patients, recruited in an Italian tertiary care asthma clinic, overweight patients were different from 
normal weight patients both in terms of clinical and functional features and in terms of airway 





Patients (14 years of age and older) with asthma diagnosis according to the international 
guidelines (20) were eligible to take part in the study and were prospectively recruited over 18-
month period, from April 2010 to September 2011, from our Asthma Outpatient Clinic. In each 
patient, BMI, duration of disease, smoking habit and asthma therapy were recorded.  
 
BMI was defined as the weight in kilograms divided by the square of height in meters. In 
each subject it was calculated from patients’ self-reported height and weight. The international 
standard definition of obesity was used (21). Patients were classified as underweight (BMI <18.5 
kg/m²) normal (18.5 ≤ BMI ≥ 25 kg/m²), overweight (25 > BMI ≤ 30 kg/m²) and obese (BMI >30 
kg/m²).  
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Atopy was assessed by skin prick tests with a battery of 10 common inhalant allergens. All 
patients underwent FeNO measurement, completed the Asthma Control Test (ACT) and underwent 
spirometry, as part of their visit.  




We ensured that the patients were not affected by any acute respiratory infection and had 
followed the pre-test instructions, i.e. no nitrate-rich foods and beverages, including alcoholic ones, 
no tobacco smoking and no exercise within 1 h preceding the test, as these factors can affect the test 
results. Moreover, all patients underwent FeNO measurement before lung function test. Only 
patients able to perform at least two acceptable FeNO measurements were included in the analysis. 
FeNO was measured according to the ATS/ERS guidelines (22) using a FeNO stationary 
chemiluminescence analyzer (NIOX, Aerocrine AB, Solna, Sweden).  
 
All FeNO measurements were performed at the same time of day (± 2 h) to allow a possible 
circadian rhythm effect. In detail, patients were seated in the upright position without a nose clip 
and were asked to inhale nitric oxide-free air through a filter connected to the device deeply to total 
lung capacity and then to exhale for 10s at a constant pressure guided by a visual cue to stabilize 
flow rate. All tests were performed at an exhalation pressure of 10-20 cm H2O, to maintain a fixed 
flow-rate of 50 ml/s. Measurements were repeated after a brief rest period until two acceptable 
values (±2.5 ppb for measurements <50 ppb and ±5 % for measurements ≥50 ppb) were performed 
(maximum six attempts). The mean of two adequate values for each subject was recorded for 




Asthma Control Assessment 
Asthma control was assessed using the Italian version of the Asthma Control Test (23). 
Patients subjectively evaluated the degree of impairment caused by their disease during the 
preceding four weeks by responding to five questions using a five-point-scale. The ACT is reliable, 
valid, and responsive to changes in asthma control over time (23, 24). The sum of the scores of the 
five questions gave the total ACT score (range 0–25).  A cutoff score of 19 or less identifies 
patients with poor controlled asthma.  
 
Lung function testing 
Lung function was measured by a flow-sensing spirometer connected to a computer for data 
analysis (CPFS/D Spirometer, MedGraphics, St Paul, MN, USA) which met American Thoracic 
Society (ATS) standards. Forced vital capacity (FVC), forced expiratory volume in the first second 
(FEV1), FEV1/FVC ratio, forced expiratory flow after 25% of the FVC has been exhaled (FEF25), 
forced expiratory flow rate over the middle 50% of the FVC (FEF25-75) were recorded. FVC, FEV1 
and FEF25-75 are expressed as absolute value and as percent of predicted value (25), FEV1/FVC as 
percent. 
 
Statistical Analysis  
The distribution of variables was assessed by means of Kolmogorov-Smirnov Goodness-of-
Fit test. Variables are expressed as mean ± SD, unless otherwise specified. Because of their non 
Gaussian distribution, FeNO values were log-transformed before analysis. Unpaired t-test, Mann 
Whitney test and Pearson chi square test were used for comparisons, when appropriate. To examine 
relationships between measures Pearson’s correlation coefficient (r) and Spearman rank order 
correlation coefficient (rs) were used, when appropriate. Logistic regression analysis was performed 
to test the association between the presence of overweight (dependent variable) and gender, 
smoking habit, atopy, poor controlled asthma and inhaled steroid treatment, as independent 
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variables. Odds ratios are presented with 95% confidence intervals. A p value  0.05 was 




Of the 422 patients who agreed to participate in the study, 14 had a BMI ≤ 18. 5 kg/m² 
(3.3%), 203 had BMI > 18.5 and ≤ 25 kg/m² (44.6%) and 205 had BMI > 25 kg/m² (48.6%). Out of 
205 patients with elevated BMI, one hundred forty-five patients were overweight (34.3%) and 60 
were obese (14.2%). Underweight and obese patients were excluded from the study, leaving 348 
patients suitable from the final analysis (Table 1). 
 
The overweight patients were significantly older than patients with normal BMI (p<0.001). 
The majority of the patients were atopic (75%) with no difference between the two subgroups of  
patients (Table 1).  Patients with normal BMI did not also differ from patients with increased BMI 
in gender distribution, disease duration and smoking habit (Table 1). In the two subgroups of 
patients, the ratio between the number of patients treated with inhaled steroids and that of untreated 
patients tended to be significantly higher in overweight patients, as compared to  normal weight 
patients (104/41 vs 130/73; chi square= 2.268, p=0.082) (Table 1). In all patients, spirometry ranged 
from a severe obstructive ventilatory defect to normal value (FEV1/FVC range: 45 to 98 % and 
FEV1 range: 43% to 137%) (Table 1). 
 
The spirometry values were significantly lower in overweight patients, as compared to the 
corresponding ones in normal weight patients (Table 1). Notably, FEF25-75 values, even when 
normalized for FVC, were significantly lower in overweight patients (Table 1). Additionally, in all 
patients an inverse significant correlation was found between BMI and FEV1 (r=-0.154; p= 0.004), 
FEV1/FVC (r= -0.233; p< 0.001), and FEF25-75 (r= -0.152; p< 0.005).  
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The ACT score was significantly different between overweight and normal weight patients 
(Table 1). In the two subgroups of patients, the ratio between the number of patients with well 
controlled asthma (ACT > 20) and that of patients with poor controlled asthma (ACT ≤ 19) was 
significantly lower in overweight patients, as compared to patients with normal BMI (1.07 vs 1.84; 
chi square= 6.030, p=0.01) (Figure 1). In the whole study population, the ratio between the number 
of well controlled and poor controlled patients was 1.46. Moreover, in all patients ACT score values 
were inversely related to BMI values (rs =-0.170; p< 0.001). Logistic regression analysis showed 
that overweight was significantly associated to poor controlled asthma, but not to gender, smoking 
habit, atopy and inhaled steroids (Table 2).  
 





The main finding of the present study is that overweight patients with asthma had worse 
spirometry and disease control, as compared with normal weight patients, regardless of the gender, 
smoking habit and atopy. The percent of patients who were receiving inhaled steroids tended to be 
higher among overweight patients than normal weight patients. Importantly, no significant 
difference in airway inflammation, assessed by FeNO measurement, was found between the two 
groups of patients. Lastly, as it has been reported in the Italian general population (26), we found 
that increased BMI becomes more common with increasing age, additionally our results also 
indicate a high rate of obese among adult asthmatics seen in an Italian tertiary care asthma clinic. 
 
Physiologically, an elevated BMI may affect lung volumes, with no direct effect on airway 
caliber (27). Spirometric variables, such as FVC and FEV1, tend to decrease with increasing BMI 
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with no change or increase in FEV1/FVC (26). Expiratory flows decrease with increasing weight in 
proportion to the lung volume and, in obese patients, specific airway resistance, calculated by 
adjusting for the lung volume at which the measurement were made, is in the normal range (27). 
Whether or not asthma and elevated BMI may interact on lung function has been so far little 
investigated. In a large group of subjects with normal values for airway function, but a wide range 
of BMI, including subjects with working diagnosis of asthma, Jones et al. (28) showed a significant 
linear relationship between BMI and lung volumes with no change in FEV1/FVC. The study did not 
provide any separate analysis for asthmatic and non asthmatic subjects. In a large cohort of young 
adults aged 28-30 yrs, King et al (29) found that after adjusting data for smoking and asthma, 
elevated BMI was associated with reduced lung volume, which was in turn linked with airway 
narrowing, as assessed by the airway conductance. Interestingly, this study showed that the 
reduction in airway calibre was only partly related to the reduction in lung volume, suggesting other 
nonvolume-related mechanisms.    
 
In this study, we found that flow-volume curve parameters, such as FVC, FEV1 and FEF25-
75, were significantly lower in overweight asthmatic patients than those of normal weight patients. 
Interestingly, when compared to normal weight patients, the reductions in FVC and in FEV1 were 
not affected to the same extent in overweight patients, since in these patients the FEV1/FVC ratio 
was significantly lower. In addition, even when normalized for FVC, the FEF25-75 values were 
significantly lower in overweight patients. Taken together these findings indicate that overweight 
patients, as compared to normal weight patients, had higher degree of both proximal and peripheral 
airflow obstruction, which was greater than expected on the basis of the reduction in lung volume.  
 
The increased airflow obstruction, which we found in overweight patients, cannot refer to an 
increase in airway inflammation, as assessed by FeNO measurement, since these patients did not 
differ from normal weight patients in this parameter. Asthmatic patients with elevated BMI, as 
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compared to normal weight patients do not appear to have increased airway cellular inflammation 
[30]. Notably, it seems also likely that the elevated BMI does not contribute to asthma through 
conventional Th type 2-mediated inflammatory pathways (30). In obese patients, it has been also 
hypothesised that airway structures could be remodelled by exposure to proinflammatory 
adipokines or damaged by the continual opening and closing of small airways throughout the 
breathing cycle (30) and one cannot exclude that even in overweight asthmatic patients these 
mechanisms may play a role. 
 
In the present study, overweight patients had worse disease control and tended to take more 
inhaled steroids, as compared to normal weight patients. Patients with elevated BMI may 
experience wheezing and breathlessness due to their excess weight (31) and, consequently, may 
falsely attribute weight-related respiratory symptoms to asthma, causing increased medication use 
(32). However, this explanation could be only partly taken into account for our results, since 
overweight patients had a greater degree of airflow obstruction, to which the asthmatic symptoms 
could be attributed. In this context, it is conceivable that in overweight patients inhaled steroid 
therapy even increased, as compared to normal weight patients, was not enough to the disease 
control. It is of note that an increase in BMI was associated with an increase in the delay/avoidance 
of health care (33). In other words, in overweight patients behavioral factors could condition self-
management both in terms of asthma control and in terms of diet and physical activity.  
 
Previous studies provided discordant results on the relationship between asthma and 
elevated BMI, showing a poor (3,4) or similar (6) asthma control in obese patients, in comparison to 
normal weight patients. Notably, studies showing poor control (3,4) recruited patients in outpatient 
clinics, whereas the study showing no difference (6) recruited their patients in community-based 
outpatients primary care practices. Moreover, there are some difference between all these study and 
ours. These studies (3,4,6) were mainly addressed to obese patients and did not provide any 
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information on the airway inflammation of the patients. Notably, only in one study (4) the patients 
were assessed by spirometry, which showed a reduction of FVC values in obese patients, when 
compared to normal weight patients. 
 
As compared to the Italian general population (26), in our cohort of patients we found a 
higher rate of obese patients. Our data are consistent with the results of a previous Canadian report 
(4) and suggest that in industrialized countries, obesity may be more common among adult tertiary 
care asthmatics than in the general population. This finding could be due to the fact that asthmatic 
patients followed at a tertiary care hospital may have likely more co-morbidity than patient 
followed by primary care physicians.   
 
We acknowledge that this study has some limitations. Firstly, we defined normal weight and 
overweight only in terms of BMI and we cannot exclude that other measures of excess body weight, 
such as waist-hip ratio or waist circumference, might better clarify the impact of increasing body fat 
on asthma. However, what is the best risk factor among adiposity measures is still debatable (34). 
Additionally, we calculated the BMI using self-reported height and weight. It has been reported 
that, despite the high correlation between measured and self-reported data, the prevalence of 
overweight calculated from measured values was higher than that calculated from self-reported 
values among older adults (35). When calculated with self-reported height, BMI was one unit lower 
than when calculated from measured height for persons older than 70 years (35). As the most of our 
patients was young adults (median age 41 yrs, 30-54 yrs 25%-75% percentile),we are confident in 
our estimates of BMI.       
 
In conclusion, although we cannot infer any cause-effect relationship between adiposity and 
clinical and functional features of asthma from our data, the present study shows that preobese 
asthmatic patients are at increased risk of airflow obstruction and of poor disease control. This study 
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also supports the view that other factors than airway inflammation alone may explain the 
relationship between elevated BMI and asthma and further underlines the relevance which 
behavioural factors may have in the management of asthma. 
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BMI > 18. 5 ≤ 25 kg/m2 
(n=203) 
BMI > 25 ≤ 30 kg/m2 
 (n=145) p value 
Age (years) 43  16 37  15 48  16 <0.001 
Gender (M/F) 0.65 0.65 0.65 0.537 
Atopy (Yes/No) 3.00 3.41 2.54 0.143 
Disease duration (years) 11  12 11  12 11  11 0.347 
Smoking habit (Yes/No) 0.18 0.19 0.17 0. 432 
Steroids (Yes/No) 2.05 1.78 2.53 0.082 
FVC (% pred) 105  16 107  15 103  18 0.045 
FVC (L) 3.93  1.14 4.16  1.09 3.61  1.12 <0.001 
FEV1 (% pred) 94  17 97  15 91  19 0.001 
FEV1 (L) 2.98  0.94 3.21  0.89 2.66  0.90 <0.001 
FEV1/FVC (%) 75  9 77  9 73  9 <0.001 
FEF25-75 (% pred) 76  29 80  27 71  30 0.005 
FEF25-75 (% L/sec) 2.57  1.27 2.87  1.25 2.15  1.17 <0.001 
FEF25-75 /FVC 0.64  0.26 0.68  0.26 0.59  0.25 0.001 
ACT (0-25) 20 (17-23) 21 (18-24) 20 (16-23) 0.012 
FeNO (ppb) 39  34 40  34 39  34 0.927 
 





Table 2. Odds Ratios (95% Confidence Intervals) by regression logistic analysis of female 
gender, smoking habit, atopy, inhaled steroid therapy and poor controlled disease for 
overweight patients with asthma  
 
 OR (95% CI) p value 
Female Gender 0.903 (0.577-1.412) 0.653 
Smoking Habit 0.934 (0.508-1.718) 0.827 
Atopy 0.735 (0.446-1.211) 0.227 
Inhaled Steroids 1.292 (0.803-2.081) 0.291 


















Figure Legend  
 
Figure 1. Percent of asthmatic patients, categorized by BMI, with female gender, smoking habit, 
atopy, inhaled steroid therapy and poor controlled asthma. 
Key: NW = Normal Weight; OW = Overweight.  * p = 0.012 by chi-square 
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